Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 46

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 46
---
 The proceeds were used to redeem Grifols' Senior Unsecured             
 Notes due in May 2025. In conjunction to this, the company also successfully closed the issuance of additional EUR       
 300 million private placement secured notes. This amount is in addition to the initial EUR 1 billion private placement   
 completed and has the same economic terms                                                                                
 On December 19, 2024, Grifols successfully completed another private placement of EUR 1.3 billion of 7.125%              
 senior secured notes maturing in May 2030 issued at par. The proceeds from this placement were used to redeem            
 Grifols' 1.625% Senior Secured Notes due in February 2025, fully repay the outstanding revolving loans maturing in       
 November 2025, and for general corporate purposes. Taken as a whole, these transactions were leverage-neutral. In        
 conjunction with these offerings, Grifols also entered into an agreement to partially extend and upsize its Revolving    
 Credit Facility (RCF) through May 2027. These transactions successfully concluded Grifols' efforts to significantly      
 deleverage its balance sheet, proactively manage all its debt maturities, and strengthen its overall liquidity position. 
 CAPITAL EXPENDITURES (CAPEX)                                                                                             
 In 2024, Grifols advanced its capital investment plan to expand and improve the production facilities of its business    
 units. The company has greatly optimized its CAPEX resource allocations considering the investments already made         
 in recent years. In 2024, capital expenditures related to Property, Plant and Equipment (PP&E) additions stood at        
 EUR 232 million (EUR 224 million in 2023). The investments in 2024 and prior have well positioned the company            
 to satisfy growth and expansion.                                                                                         
 CORPORATE TRANSACTIONS AND ACQUISITIONS                                                                                  
 Completion of the Sale of SRAAS equity stake to Haier                                                                    
 On June 18, 2024 Grifols completed the sale of a 20% equity stake in Shanghai RAAS (SRAAS) to Haier Group                
 Corporation (Haier Group) and forged a strategic alliance with Haier Group. The alliance leverages synergies             
 between Grifols’ industry-leading plasma and diagnostic excellence and Haier Group’s preeminent portfolio of             
 healthcare solutions to innovate and contribute to SRAAS’ growth in the long run. In the terms of the share purchase     
 agreement, Grifols sold a 20% equity stake in S